<code id='ED1D286AC3'></code><style id='ED1D286AC3'></style>
    • <acronym id='ED1D286AC3'></acronym>
      <center id='ED1D286AC3'><center id='ED1D286AC3'><tfoot id='ED1D286AC3'></tfoot></center><abbr id='ED1D286AC3'><dir id='ED1D286AC3'><tfoot id='ED1D286AC3'></tfoot><noframes id='ED1D286AC3'>

    • <optgroup id='ED1D286AC3'><strike id='ED1D286AC3'><sup id='ED1D286AC3'></sup></strike><code id='ED1D286AC3'></code></optgroup>
        1. <b id='ED1D286AC3'><label id='ED1D286AC3'><select id='ED1D286AC3'><dt id='ED1D286AC3'><span id='ED1D286AC3'></span></dt></select></label></b><u id='ED1D286AC3'></u>
          <i id='ED1D286AC3'><strike id='ED1D286AC3'><tt id='ED1D286AC3'><pre id='ED1D286AC3'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:324

          Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

          advertisement

          For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets

          ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Cancer, immunology, HIV research ensnared in fetal tissue politics

          MollyFergusonforSTATScientistsattheUniversityofWisconsin-Madisonhavespentyearstryingtounravelthedeta